Combined Therapy with Cisplatin and Interferon α-2b (INTRON-A) in Patients with Penile Carcinoma. Analysis of 2'5’ oligo (A) Synthetase and Circulating Interferon
Restricted accessLetterFirst published online January, 1996
Combined Therapy with Cisplatin and Interferon α-2b (INTRON-A) in Patients with Penile Carcinoma. Analysis of 2'5’ oligo (A) Synthetase and Circulating Interferon
MitropoulosD., DimopoulosM.A., Kiroudi-VulgariA.Neoadjuvant cisplatin and interferon α-2b in the treatment and organ preservation of penile carcinoma. Urol1994; 152: 1124–6.
2.
CascinaS., FedeliA., LuziF.S.5-Fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. Br J Cancer1994; 69: 392–3.
3.
EronL.J., JudsonF., TuckerS.Interferon therapy for condylomata acuminata. New Engl J Med1986; 315: 1059.
4.
PyrhönenS., MaicheA.G., MäntyjävriR.Verrucous carcinoma of the penis successfully treated with interferon. Br J Urol1991; 68: 102.
5.
JohustonM.I., TorrenceP.F.The role of interferon induced proteins, ds-RNA and 2'5’ oligoadenylate in the interferon-mediated inhibition of viral translation. In: FriedmanR.M., ed. Interferon, Vol 3. Amsterdam: Elsevier, 1984; 177–298.
6.
SchattnerA., MerlinC., WallachD.Monitoring of interferon therapy by assay of (2′–5′) oligo-isoadenylate synthetase in human peripheral white blood cells. Interferon Res1981; 1: 587–94.
7.
WilliamsB.R.G., ReadS.E., FreedmanM.H.The assay of 2′5′ A synthetase a an indicator of interferon activity and virus infection in vivo. In: MeriganT.C., ed. Interferons, New York: Academic Press, 1982; 253–67.
8.
VakalikosJ., DimasisN., BoutisL.Combined treatment of advanced renal cell carcinoma and monitoring of the patients with two different parameters. Acta Urol Ital1993; 2: 91–4.
9.
NakajimaS., KurokiT., ShiataniM.Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatology1990; 12: 1261–5.
